Factor-VII activating protease (FSAP) is a ubiquitously circulating zymogen plasma serine protease, which is rapidly activated upon tissue injury. FSAPs role in sepsis, trauma, stroke, and acute respiratory distress syndrome suggests that pro-FSAP activation is...
Nextera’s unique NextCore display technology combined with state-of-the-art computational guidance efficiently generates low picomolar affinity TCR-Like antibodies
The antibody engineering field is steadily evolving harnessing improvements in discovery engines and computational methods. Together with collaborators at OUS/UiO (Norway) and John Hopkins (US), we here describe a very powerful combination of the highly efficient...
Nextera AS announces strategic collaboration with Zelluna Immunotherapy AS on development of optimized TCRs for redirected cancer immunotherapy
Nextera AS, a drug and target discovery company built on the unique and novel NextCore protein engineering and discovery platform, announces a strategic collaboration with Zelluna Immunotherapy AS on optimizing T cell receptors (TCRs) for subsequent implementation...
Oslo, Norway, 7. June, 2021 – Nextera AS, a drug and target discovery company built on a unique and novel phage display discovery platform, NextCore, announces the appointment of Dr. Bent Jakobsen to its Board of Directors.
Nextera receives Norwegian Research Council funding to expand its NextCore platform with a novel therapeutic T cell receptor discovery pipeline.
Nextera is very pleased to announce that the Norwegian Research Council (NRC) has awarded a prestigious 15.7 MNOK grant funding to expand our NextCore platform with a novel discovery T cell receptor (TCR) discovery pipeline.
The Nextera patent “Multivalent phage display systems and methods” was granted by the USPTO 8.1.2020.
January 1st. Dr. Ole Henrik Brekke joined Nextera as the Chief Business Officer. Ole Henrik has a strong track record in developing companies from the idea stage into successful clinical stage.